| Literature DB >> 27171008 |
Muhammad Farooq Rai1, Linda J Sandell1,2,3, Bo Zhang4, Rick W Wright1, Robert H Brophy1.
Abstract
OBJECTIVES: (i) To provide baseline knowledge of gene expression in macroscopically normal articular cartilage, (ii) to test the hypothesis that age, body-mass-index (BMI), and sex are associated with cartilage RNA transcriptome, and (iii) to predict individuals at potential risk for developing "pre-osteoarthritis" (OA) based on screening of genetic risk-alleles associated with OA and gene transcripts differentially expressed between normal and OA cartilage.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27171008 PMCID: PMC4865200 DOI: 10.1371/journal.pone.0155373
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of study participants and quality of RNA samples.
| Patient # | Age (years) | BMI (kg/m2) | Sex | Time from injury (months) | Smoking | Diabetes | RIN |
|---|---|---|---|---|---|---|---|
| P4-001 | 37 | 21.9 | Female | 26 | No | No | 7.4 |
| P4-002 | 45 | 28.8 | Male | 20 | No | No | 6.7 |
| P4-003 | 62 | 27.8 | Female | 9 | No | No | 7.1 |
| P4-004 | 58 | 20.5 | Female | 5 | No | No | 6.8 |
| P4-005 | 31 | 24.3 | Female | 8 | No | No | 8.1 |
| P4-007 | 53 | 26.6 | Male | 2 | No | No | 7.0 |
| P4-008 | 50 | 28.5 | Male | 21 | No | No | 6.9 |
| P4-009 | 65 | 27.1 | Female | 12 | No | No | 7.0 |
| P4-010 | 53 | 32.0 | Male | 2 | No | No | 6.7 |
| P4-011 | 43 | 34.4 | Male | 2.5 | No | No | 6.5 |
| P4-012 | 40 | 24.5 | Male | 18 | No | No | 6.8 |
| P4-013 | 53 | 26.3 | Male | 2 | No | No | 6.7 |
| - | - | ||||||
BMI = Body mass index; RIN = RNA integrity number
Fig 1Pictorial representation of microarray data.
Microarray analysis of human healthy articular cartilage was conducted to assess the effect of age, BMI, and sex. A. Venn diagrams represent the number of differentially expressed genes in each comparison. Values in parentheses are the numbers of differentially expressed genes. Values in overlapping areas are the numbers of genes common to any two comparisons. B. Numbers of differentially expressed gene transcripts across all three factors are shown. Number of gene transcripts shown for age and BMI indicate positively (red) and negatively (green) correlated gene transcripts while for sex they represent up-regulated (red) and down-regulated (green) gene transcripts in females versus males. C. Hierarchical clustering map, representing the transcripts that were significantly (P<0.05) differentially expressed between the two sexes is shown. Each vertical row depicts a single sample, and each horizontal line stands for a single gene transcript. Green color indicates down-regulated gene transcripts while red color indicates up-regulated gene transcripts. D. The differentially expressed gene transcripts at all fold changes are shown in the form of volcano plots to show the trend of expression by P value (y axes) and fold change (x axes). Gene transcripts outside the thick black lines are those that have ≥1.5 fold expression x = gene transcripts with lowest P value (statistically highly significant) y = gene transcripts with highest fold change (biologically highly significant), green circles = gene transcripts down-regulated in females, red circles = gene transcripts up-regulated in females, N/C = no change.
Selected list of gene transcripts correlated with age and BMI*.
| tuberous sclerosis 2 | 0.004 | 0.81 | 6 phosphofructo 2 kinase/fructose 2,6 biphosphatase 2 | 0.001 | 0.87 | |||
| snail family zinc finger 2 | 0.004 | 0.81 | 0.001 | 0.87 | ||||
| solute carrier family 35, member E1 | 0.003 | 0.81 | CD14 molecule | 0.001 | 0.84 | |||
| DCN1, Defective In Cullin Neddylation 1 –antisense RNA 2 | 0.004 | 0.80 | Fc fragment of IgG, low affinity IIb, receptor | 0.002 | 0.82 | |||
| phosphatidylinositol 3,4,5 trisphosphate dependent Rac exchange factor 2 | 0.005 | 0.80 | T cell activation RhoGTPase activating protein | 0.003 | 0.82 | |||
| interferon induced transmembrane protein 2 | 0.004 | 0.79 | olfactory receptor, family 2, subfamily M, member 3 | 0.002 | 0.82 | |||
| DOT1 like histone H3K79 methyltransferase | 0.004 | 0.79 | solute carrier 8 family A1 –antisense RNA 1 | 0.003 | 0.82 | |||
| syntaxin binding protein 4 | 0.002 | 0.79 | disrupted in renal carcinoma 3 | 0.003 | 0.81 | |||
| Moloney leukemia virus 10, homolog | 0.005 | 0.79 | ATPase, class I, type 8B, member 4 | 0.003 | 0.81 | |||
| cyclin M3 | 0.006 | 0.78 | Ras association (RalGDS/AF 6) domain family member 2 | 0.004 | 0.80 | |||
| cyclin dependent kinase 2 | 0.005 | 0.78 | matrix metallopeptidase 24 –antisense RNA 1 | 0.000 | 0.80 | |||
| RAD51 antisense RNA 1 | 0.007 | 0.78 | FYVE, RhoGEF and PH domain containing 2 | 0.005 | 0.79 | |||
| zinc finger protein 546 | 0.005 | 0.77 | 0.006 | 0.78 | ||||
| tribbles pseudokinase 2 | 0.005 | 0.77 | transcription elongation factor A (SII) like 3 | 0.007 | ||||
| solute carrier family 25 (mitochondrial iron transporter), member 37 | 0.007 | 0.77 | cytohesin 1 interacting protein | 0.007 | 0.77 | |||
| solute carrier family 39 (zinc transporter), member 1 | 0.005 | 0.77 | neutrophil cytosolic factor 1B | 0.007 | 0.77 | |||
| XPA binding protein 2 | 0.007 | 0.76 | solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8 | 0.007 | 0.77 | |||
| TAF6 like RNA polymerase II, p300/CBP associated factor (PCAF) associated factor | 0.008 | 0.76 | RAB11 family interacting protein 1 | 0.007 | 0.77 | |||
| germ cell less, spermatogenesis associated 1 | 0.006 | 0.75 | POTEE | POTE ankyrin domain family, member E | 0.007 | 0.76 | ||
| ring finger protein 1 | 0.009 | 0.75 | protein phosphatase, EF hand calcium binding domain 1 antisense RNA 1 | 0.011 | 0.76 | |||
| cytochrome P450, family 7, subfamily A, polypeptide 1 | 0.001 | 0.85 | excision repair cross complementation group 2 | 0.002 | 0.80 | |||
| transmembrane protein 235 | 0.001 | 0.82 | tripartite motif containing 49 | 0.004 | 0.80 | |||
| coiled coil domain containing 79 | 0.005 | 0.79 | growth differentiation factor 11 | 0.005 | 0.79 | |||
| solute carrier family 26 (anion exchanger), member 5 | 0.005 | 0.78 | zinc finger, FYVE domain containing 28 | 0.006 | 0.78 | |||
| zinc finger protein 852 | 0.006 | 0.78 | aralkylamine N acetyltransferase | 0.006 | 0.78 | |||
| discoidin domain receptor tyrosine kinase 1 | 0.004 | 0.77 | late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 | 0.004 | 0.78 | |||
| leucine rich repeat containing 2 | 0.007 | 0.77 | bile acid CoA: amino acid N acyltransferase | 0.007 | 0.78 | |||
| LY6/PLAUR domain containing 6 | 0.008 | 0.77 | digestive organ expansion factor homolog | 0.003 | 0.77 | |||
| free fatty acid receptor 1 | 0.008 | 0.76 | FYVE, RhoGEF and PH domain containing 1 | 0.008 | 0.77 | |||
| immunoglobulin lambda variable 4 | 0.008 | 0.76 | solute carrier family 35, member B1 | 0.010 | 0.76 | |||
| cadherin-related family member 3 | 0.010 | 0.76 | transmembrane protein 243 | 0.002 | 0.76 | |||
| regulator of G protein signaling 21 | 0.011 | 0.75 | hexamethylene bis acetamide inducible 1 | 0.010 | 0.76 | |||
| ataxin 3 like | 0.008 | 0.75 | MHC class I polypeptide-related sequence B | 0.010 | 0.75 | |||
| Ras association (RalGDS/AF 6) domain family (N terminal) member 10 | 0.012 | 0.75 | histone cluster 1, H2aj | 0.010 | 0.75 | |||
| sorbin and SH3 domain containing 2 | 0.013 | 0.74 | coiled coil domain containing 28B | 0.015 | 0.73 | |||
| hydroxyacid oxidase 2 | 0.007 | 0.74 | zinc finger protein 846 | 0.008 | 0.73 | |||
| RIC8 guanine nucleotide exchange factor A | 0.014 | 0.73 | phosphoglycolate phosphatase | 0.003 | 0.73 | |||
| solute carrier family 6 (neutral amino acid transporter), member 15 | 0.008 | 0.73 | 0.004 | 0.73 | ||||
| arylacetamide deacetylase like 4 | 0.011 | 0.73 | family with sequence similarity 174 | 0.016 | 0.72 | |||
| ankyrin 1 | 0.008 | 0.73 | neurexophilin 4 | 0.014 | 0.72 | |||
*Top 20 gene transcripts highly correlated with age and BMI are shown.
BMI = body mass index, r = correlation coefficient
Biological processes represented by differentially expressed gene transcripts by age, BMI, and sex.
| regulation of intracellular signal transduction | 9.504E-10 | 3.476E-06 | immune response | 2.558E-15 | 1.051E-11 |
| regulation of signal transduction | 1.095E-08 | 2.002E-05 | innate immune response | 9.620E-13 | 1.977E-09 |
| regulation of fat cell differentiation | 5.523E-08 | 6.733E-05 | defense response | 4.465E-12 | 6.117E-09 |
| regulation of cell communication | 9.753E-08 | 8.243E-05 | myeloid leukocyte activation | 3.507E-11 | 3.603E-08 |
| necroptotic process | 1.127E-07 | 8.243E-05 | immune system process | 6.500E-11 | 5.343E-08 |
| regulation of signaling | 2.080E-07 | 1.268E-04 | leukocyte activation | 9.098E-11 | 6.232E-08 |
| regulation of cellular protein metabolic process | 2.838E-07 | 1.458E-04 | positive regulation of cell activation | 1.980E-10 | 1.163E-07 |
| positive regulation of neurotransmitter transport | 3.190E-07 | 1.458E-04 | regulation of immune system process | 2.873E-10 | 1.476E-07 |
| regulation of establishment of protein localization | 5.196E-07 | 2.111E-04 | regulation of immune response | 8.050E-10 | 3.676E-07 |
| positive regulation of muscle contraction | 6.796E-07 | 2.307E-04 | response to cytokine | 1.499E-09 | 6.160E-07 |
| positive regulation of memory T cell activation | 1.952E-11 | 1.950E-08 | response to mineralocorticoid | 1.252E-06 | 3.061E-03 |
| regulation of multicellular organismal process | 6.924E-10 | 2.767E-07 | response to toxic substance | 2.288E-06 | 3.061E-03 |
| positive regulation of multicellular organismal process | 1.451E-09 | 5.271E-07 | adenylate cyclase modulating G protein receptor signaling | 3.273E-06 | 3.061E-03 |
| tolerance induction | 3.325E-09 | 1.022E-06 | adenylate cyclase inhibiting serotonin receptor signaling | 4.652E-06 | 3.061E-03 |
| regulation of system process | 6.153E-09 | 1.639E-06 | cellular response to estrogen stimulus | 5.894E-06 | 3.061E-03 |
| regulation of response to external stimulus | 7.850E-09 | 1.960E-06 | cellular response to abiotic stimulus | 7.710E-06 | 3.061E-03 |
| positive regulation of interferon gamma production | 1.448E-08 | 3.095E-06 | negative regulation of synaptic transmission, GABAergic | 7.947E-06 | 3.061E-03 |
| G protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 1.674E-08 | 3.344E-06 | rhodopsin mediated signaling pathway | 9.845E-06 | 3.061E-03 |
| cell-cell signaling | 2.144E-08 | 4.079E-06 | regulation of endocrine process | 9.845E-06 | 3.061E-03 |
| regulation of blood pressure | 2.266E-08 | 4.116E-06 | G protein coupled receptor internalization | 1.016E-05 | 3.061E-03 |
| detection of chemical stimulus involved in sensory perception of taste | 4.045E-05 | 2.702E-02 | neuron differentiation | 6.716E—11 | 1.608E-07 |
| L-ascorbic acid transport | 5.015E-05 | 2.702E-02 | tissue development | 1.064E-10 | 1.608E-07 |
| peptidyl cysteine oxidation | 5.015E-05 | 2.702E-02 | cell development | 1.096E-10 | 1.608E-07 |
| aminoglycan metabolic process | 8.458E-05 | 2.702E-02 | cell differentiation | 1.534E-10 | 1.688E-07 |
| chaperone mediated protein folding | 9.212E-05 | 2.702E-02 | cellular developmental process | 5.230E-10 | 4.605E-07 |
| negative regulation of cysteine type endopeptidase activity involved in apoptotic process | 1.050E-04 | 2.702E-02 | heart development | 1.716E-09 | 1.098E-06 |
| regulation of cysteine type endopeptidase activity involved in apoptotic process | 1.235E-04 | 2.702E-02 | system development | 1.769E-09 | 1.098E-06 |
| glycosaminoglycan biosynthetic process | 1.426E-04 | 2.702E-02 | heart morphogenesis | 2.193E-09 | 1.098E-06 |
| mitotic cell cycle checkpoint | 1.452E-04 | 2.702E-02 | anatomical structure morphogenesis | 2.244E-09 | 1.098E-06 |
| detection of chemical stimulus involved in sensory perception of bitter taste | 2.664E-04 | 3.950E-02 | circulatory system development | 3.306E-09 | 1.323E-06 |
BMI = body mass index, FDR = false discovery rate
Fig 2Biological processes associated with age.
Based on statistical significance i.e. -log (P value) as determined by IPA analysis, the biological processes positively (A) and negatively (B) associated with age are shown.
Fig 3Biological processes associated with BMI.
Based on statistical significance i.e. -log (P value) as determined by IPA analysis, the biological processes positively (A) and negatively (B) associated with BMI are shown.
Selected list of gene transcripts differentially expressed by sex*.
| S100 calcium binding protein A8 | 0.032 | 157.62 | 53.40 | 2.95 | 2.95 | |
| coiled coil domain containing 144A | 0.024 | 75.20 | 31.99 | 2.35 | 2.35 | |
| casein alpha s1 | 0.048 | 21.14 | 9.26 | 2.28 | 2.28 | |
| mesenteric estrogen dependent adipogenesis | 0.039 | 160.68 | 73.58 | 2.18 | 2.18 | |
| triggering receptor expressed on myeloid cells like 5 | 0.005 | 20.45 | 10.22 | 2.00 | 2.00 | |
| integrin, beta like 1 | 0.049 | 562.50 | 298.70 | 1.88 | 1.88 | |
| 0.038 | 899.71 | 478.62 | 1.88 | 1.88 | ||
| casein kinase 2, alpha 3 polypeptide | 0.025 | 41.67 | 22.30 | 1.87 | 1.87 | |
| speedy/RINGO cell cycle regulator family member E5 | 0.045 | 69.83 | 37.60 | 1.86 | 1.86 | |
| Uronyl 2 sulfotransferase | 0.040 | 6.24 | 5.47 | 1.71 | 1.71 | |
| secretory leukocyte peptidase inhibitor | 0.013 | 39.84 | 114.70 | 0.35 | 2.88 | |
| secreted frizzled-related protein 2 | 0.041 | 29.77 | 69.61 | 0.43 | 2.34 | |
| carcinoembryonic antigen-related cell adhesion molecule 5 | 0.028 | 7.34 | 13.46 | 0.55 | 1.83 | |
| HLA complex group 22 | 0.007 | 14.89 | 25.59 | 0.58 | 1.72 | |
| MT RNR2 like 4 | 0.050 | 6.42 | 10.70 | 0.60 | 1.67 | |
| podocalyxin like | 0.032 | 43.40 | 70.96 | 0.61 | 1.64 | |
| THRB antisense RNA 1 | 0.039 | 11.11 | 18.17 | 0.61 | 1.63 | |
| cytochrome P450, family 2, subfamily C, polypeptide 8 | 0.037 | 7.83 | 12.75 | 0.61 | 1.63 | |
| developmental pluripotency associated 2 | 0.003 | 4.67 | 7.59 | 0.61 | 1.63 | |
| olfactory receptor, family 5, subfamily D, member 14 | 0.024 | 16.31 | 26.23 | 0.62 | 1.61 | |
*top 10 gene transcripts differentially expressed between males and females are shown.
LS = least squares
Fig 4Biological processes associated with sex.
Based on statistical significance i.e. -log (P value) as determined by IPA analysis, the biological processes elevated in females (A) and males (B) are shown.
Gene transcripts common to age, BMI and sex*.
| 0.000 | 0.86 | 0.008 | -0.48 | 0.007 | -1.39 | Down-regulated in females | |
| 0.001 | 0.85 | 0.036 | -0.39 | 0.017 | -1.23 | Down-regulated in females | |
| 0.002 | 0.80 | 0.032 | -0.44 | 0.014 | -1.21 | Down-regulated in females | |
| 0.005 | 0.74 | 0.045 | -0.46 | 0.025 | -1.44 | Down-regulated in females | |
| 0.005 | 0.68 | 0.005 | -0.67 | 0.030 | -1.21 | Down-regulated in females | |
| 0.014 | 0.66 | 0.023 | -0.59 | 0.049 | -1.34 | Down-regulated in females | |
| 0.015 | 0.62 | 0.038 | -0.50 | 0.012 | -1.29 | Down-regulated in females | |
| 0.007 | 0.62 | 0.042 | -0.41 | 0.003 | -1.30 | Down-regulated in females | |
| 0.028 | 0.60 | 0.039 | -0.56 | 0.042 | -1.26 | Down-regulated in females | |
| 0.019 | 0.59 | 0.029 | -0.53 | 0.009 | -1.33 | Down-regulated in females | |
| 0.030 | 0.58 | 0.025 | -0.60 | 0.031 | -1.23 | Down-regulated in females | |
| 0.038 | 0.57 | 0.031 | -0.60 | 0.049 | -1.31 | Down-regulated in females | |
| 0.040 | 0.57 | 0.036 | -0.58 | 0.049 | -1.77 | Down-regulated in females | |
| 0.030 | 0.56 | 0.042 | -0.52 | 0.014 | -1.51 | Down-regulated in females | |
| 0.028 | 0.56 | 0.014 | -0.66 | 0.020 | -1.30 | Down-regulated in females | |
| 0.043 | 0.53 | 0.017 | -0.66 | 0.039 | -1.26 | Down-regulated in females | |
| 0.023 | 0.52 | 0.006 | -0.68 | 0.004 | -1.19 | Down-regulated in females | |
| 0.029 | 0.50 | 0.004 | -0.75 | 0.007 | -1.25 | Down-regulated in females | |
| 0.015 | 0.49 | 0.001 | -0.80 | 0.045 | -1.15 | Down-regulated in females | |
| 0.044 | 0.47 | 0.013 | -0.63 | 0.005 | -1.28 | Down-regulated in females | |
| 0.035 | 0.46 | 0.003 | -0.77 | 0.005 | -1.43 | Down-regulated in females | |
| 0.031 | 0.44 | 0.021 | -0.48 | 0.001 | -1.37 | Down-regulated in females | |
| 0.041 | 0.41 | 0.009 | 0.58 | 0.008 | 1.50 | Up-regulated in females | |
| 0.007 | 0.39 | 0.001 | -0.60 | 0.000 | -1.74 | Down-regulated in females | |
| 0.045 | 0.39 | 0.001 | -0.86 | 0.012 | -1.23 | Down-regulated in females | |
| 0.034 | -0.42 | 0.003 | 0.66 | 0.001 | 1.26 | Up-regulated in females | |
| 0.007 | -0.45 | 0.000 | 0.86 | 0.020 | 1.32 | Up-regulated in females | |
| 0.033 | -0.48 | 0.003 | 0.79 | 0.016 | 1.33 | Up-regulated in females | |
| 0.048 | -0.49 | 0.009 | 0.73 | 0.040 | 1.28 | Up-regulated in females | |
| 0.011 | -0.50 | 0.001 | 0.84 | 0.005 | 1.41 | Up-regulated in females | |
| 0.006 | -0.53 | 0.000 | 0.83 | 0.013 | 1.27 | Up-regulated in females | |
| 0.034 | -0.53 | 0.028 | 0.55 | 0.008 | 1.42 | Up-regulated in females | |
| 0.024 | -0.54 | 0.007 | 0.69 | 0.010 | 1.32 | Up-regulated in females | |
| 0.030 | -0.54 | 0.024 | 0.58 | 0.010 | 1.36 | Up-regulated in females | |
| 0.036 | -0.55 | 0.019 | 0.65 | 0.038 | 1.28 | Up-regulated in females | |
| 0.029 | -0.56 | 0.016 | 0.64 | 0.017 | 1.24 | Up-regulated in females | |
| 0.016 | -0.59 | 0.006 | 0.70 | 0.020 | 1.52 | Up-regulated in females | |
| 0.008 | -0.59 | 0.002 | 0.77 | 0.013 | 1.26 | Up-regulated in females | |
| 0.027 | -0.59 | 0.037 | 0.55 | 0.023 | 1.13 | Up-regulated in females | |
| 0.026 | -0.59 | 0.020 | 0.63 | 0.041 | 1.31 | Up-regulated in females | |
| 0.030 | -0.60 | 0.044 | 0.54 | 0.045 | 1.20 | Up-regulated in females | |
| 0.006 | -0.60 | 0.002 | 0.74 | 0.003 | 1.49 | Up-regulated in females | |
| 0.016 | -0.62 | 0.023 | 0.57 | 0.016 | 1.41 | Up-regulated in females | |
| 0.008 | -0.63 | 0.007 | 0.65 | 0.006 | 1.33 | Up-regulated in females | |
| 0.007 | -0.63 | 0.030 | 0.46 | 0.004 | 1.31 | Up-regulated in females | |
| 0.018 | -0.64 | 0.036 | 0.55 | 0.036 | 1.15 | Up-regulated in females | |
| 0.009 | -0.66 | 0.022 | 0.54 | 0.010 | 1.50 | Up-regulated in females | |
| 0.010 | -0.67 | 0.020 | 0.57 | 0.018 | 1.48 | Up-regulated in females | |
| 0.011 | -0.67 | 0.022 | 0.57 | 0.022 | 1.25 | Up-regulated in females | |
| 0.003 | -0.67 | 0.002 | 0.70 | 0.046 | 1.09 | Up-regulated in females | |
| 0.001 | -0.67 | 0.017 | -0.43 | 0.040 | -1.08 | Down-regulated in females | |
| 0.002 | -0.68 | 0.002 | 0.65 | 0.002 | 1.31 | Up-regulated in females | |
| 0.007 | -0.70 | 0.038 | 0.47 | 0.012 | 1.51 | Up-regulated in females | |
| 0.005 | -0.70 | 0.032 | 0.46 | 0.007 | 1.20 | Up-regulated in females | |
| 0.001 | -0.77 | 0.003 | 0.63 | 0.015 | 1.22 | Up-regulated in females |
*Duplicate, uncharacterized and non-annotated gene transcripts were removed.
BMI = body mass index
Biological processes common to BMI age and sex*.
| cellular hypotonic response | 3.376E-09 | 7.141E-06 |
| hypotonic response | 8.812E-09 | 9.319E-06 |
| smooth muscle contraction | 4.369E-08 | 3.080E-05 |
| tonic smooth muscle contraction | 1.021E-07 | 5.398E-05 |
| positive regulation of wound healing | 1.917E-07 | 7.358E-05 |
| interleukin-12 production | 2.435E-07 | 7.358E-05 |
| interleukin-10 production | 2.435E-07 | 7.358E-05 |
| aorta smooth muscle tissue morphogenesis | 4.254E-07 | 1.125E-04 |
| calcium ion transport into cytosol | 8.911E-07 | 2.094E-04 |
| cytosolic calcium ion transport | 1.017E-06 | 2.150E-04 |
| smooth muscle tissue development | 1.506E-06 | 2.896E-04 |
| regulation of metal ion transport | 2.426E-06 | 4.276E-04 |
| bleb assembly | 2.652E-06 | 4.315E-04 |
| regulation of calcium ion transport | 3.071E-06 | 4.639E-04 |
| cellular response to osmotic stress | 4.102E-06 | 4.899E-04 |
| circulatory system development | 5.410E-06 | 4.899E-04 |
| cardiovascular system development | 5.410E-06 | 4.899E-04 |
| regulation of sphingomyelin catabolic process | 5.422E-06 | 4.899E-04 |
| regulation of phospholipid scramblase activity | 5.422E-06 | 4.899E-04 |
| positive regulation of sphingomyelin catabolic process | 5.422E-06 | 4.899E-04 |
| positive regulation of phospholipid scramblase activity | 5.422E-06 | 4.899E-04 |
| positive regulation of glucosylceramide catabolic process | 5.422E-06 | 4.899E-04 |
| regulation of glucosylceramide catabolic process | 5.422E-06 | 4.899E-04 |
| membrane depolarization during action potential | 5.749E-06 | 4.899E-04 |
| positive regulation of cell migration | 5.791E-06 | 4.899E-04 |
| calcium ion import | 6.227E-06 | 5.066E-04 |
| regulation of ion transport | 6.896E-06 | 5.280E-04 |
| positive regulation of cell motility | 6.990E-06 | 5.280E-04 |
| positive regulation of cellular component movement | 8.671E-06 | 6.324E-04 |
| positive regulation of locomotion | 9.711E-06 | 6.645E-04 |
| regulation of phospholipid catabolic process | 9.740E-06 | 6.645E-04 |
| peptidyl-threonine phosphorylation | 1.548E-05 | 1.023E-03 |
| peptidyl-threonine modification | 1.971E-05 | 1.263E-03 |
| positive regulation of endothelial cell migration | 2.756E-05 | 1.714E-03 |
| regulation of wound healing | 3.231E-05 | 1.952E-03 |
| membrane depolarization | 3.647E-05 | 2.143E-03 |
| artery morphogenesis | 3.749E-05 | 2.143E-03 |
| aorta morphogenesis | 5.251E-05 | 2.892E-03 |
| calcium-mediated signaling using extracellular calcium source | 5.398E-05 | 2.892E-03 |
| artery development | 5.698E-05 | 2.892E-03 |
| muscle contraction | 5.740E-05 | 2.892E-03 |
| calcium ion transmembrane transport | 5.744E-05 | 2.892E-03 |
| calcium ion transport | 6.194E-05 | 3.046E-03 |
| aorta development | 6.956E-05 | 3.344E-03 |
| response to hydrogen peroxide | 7.850E-05 | 3.638E-03 |
| positive regulation of ceramide biosynthetic process | 8.084E-05 | 3.638E-03 |
| positive regulation of sphingolipid biosynthetic process | 8.084E-05 | 3.638E-03 |
| blood vessel development | 9.356E-05 | 4.123E-03 |
| divalent metal ion transport | 9.724E-05 | 4.197E-03 |
| positive regulation of epithelial cell migration | 1.085E-04 | 4.434E-03 |
*as determined by GeneGo MetaCore.
BMI = body mass index, FDR = false discovery rate
Fig 5Heat map view of z-scored expression profiles of genes associated with OA risk-alleles.
Hierarchical clustering identified two clusters that have distinct expression pattern. When known, the expression pattern of OA-associated genes is provided in parentheses.
Fig 6Heat map view of z-scored expression profiles of gene transcripts differentially expressed between healthy and OA cartilage.
Hierarchical clustering separated the study patients into three distinct clusters. The list of gene transcripts used for cluster analysis was generated in a prior study by Karlsson et al. [40] that looked at the transcriptome-wide RNA expression of healthy and OA cartilage. This list represented all the expressed gene transcripts differentially expressed between healthy and OA cartilage at >15-fold difference.
Fig 7Findings from microfluidic digital PCR and comparison with microarray for selected gene transcripts.
The expression of six differentially expressed gene transcripts was validated by microfluidic-based digital PCR. The expression profile of the entire set of gene transcripts obtained from TaqMan digital PCR assay was concordant with the microarray data. Pearson correlation coefficient was calculated for age (left panel; red microarray, blue digital PCR), and BMI (center panel; red microarray, blue digital PCR) and differential expression was presented for sex (right panel; these data are presented as mean with standard error of the mean). r = correlation coefficient